Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2431
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database ; volume:21 ; number:1 ; day:18 ; month:12 ; year:2021 ; pages:1-10 ; date:12.2021
BMC pediatrics ; 21, Heft 1 (18.12.2021), 1-10, 12.2021
- Creator
-
Honda, Masataka
Horiuchi, Hideki
Torii, Tomoko
Nakajima, Akihiro
Iijima, Takeshi
Murano, Hiroshi
Yamanaka, Hisashi
Ito, Shuichi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12887-021-03051-x
- URN
-
urn:nbn:de:101:1-2022041319194099854140
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Honda, Masataka
- Horiuchi, Hideki
- Torii, Tomoko
- Nakajima, Akihiro
- Iijima, Takeshi
- Murano, Hiroshi
- Yamanaka, Hisashi
- Ito, Shuichi
- SpringerLink (Online service)
Other Objects (12)
Urate-Lowering Agents in Asymptomatic Hyperuricemia: Role of Urine Sediment Analysis and Musculoskeletal Ultrasound
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Lowering the risk of hyperuricemia and gout is associated with ideal cardiovascular health
Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Urate-Lowering Agents in Asymptomatic Hyperuricemia: Role of Urine Sediment Analysis and Musculoskeletal Ultrasound
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Lowering the risk of hyperuricemia and gout is associated with ideal cardiovascular health
Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Urate-Lowering Agents in Asymptomatic Hyperuricemia: Role of Urine Sediment Analysis and Musculoskeletal Ultrasound
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Lowering the risk of hyperuricemia and gout is associated with ideal cardiovascular health
Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study